Journal

Preserving Muscle on a GLP-1: What Is Evidence and What Is Extrapolation

The advice circulating on this is a mix of solid principle and confident guesswork. The distinction is worth knowing.

Separating the tiers of evidence

Well established. Weight loss by any method costs lean mass. Body-composition analyses put the lean-mass share of loss on high-efficacy GLP-1s in a range around 20% to 40% depending on the population.

Demonstrated in a trial. Combining semaglutide with bimagrumab, a myostatin inhibitor, reduced the lean-mass fraction from roughly 21% to about 7% in phase 2. That establishes the ratio is pharmacologically modifiable.

Physiologically reasonable, not tested here. That adequate protein intake and resistance training preserve lean mass during weight loss. This is well supported in general weight-loss literature. Whether it produces the same effect during GLP-1-driven loss, at these rates, has not been trialled.

Not established at all. That preserving lean mass on a scan preserves strength, mobility or independence. Researchers keep flagging that large trials measuring muscle function are largely absent, and that clinical measurement of function is not standardised.

Why the last gap matters most

Lean mass on a DEXA scan is a surrogate. The outcome anyone actually cares about is whether a person can carry shopping, climb stairs and get out of a chair unaided in ten years' time.

It is entirely plausible that composition tracks function. It has not been shown at scale, and a field that has learned repeatedly that surrogates can mislead should hold that distinction visibly.

What clinicians treating older patients are converging on

These recommendations appear consistently in 2026 clinical commentary for adults over 65, where the concern is sharpest. They belong in a conversation with your own clinician rather than as instructions from a website, because the specifics depend on your kidney function, your other medications and what you can sustain.

• Baseline body composition assessment before starting, so change is measured rather than assumed.
• Protein intake above general adult guidance.
• Resistance training alongside drug therapy rather than instead of it.
• Slower dose escalation than standard, to moderate the rate of loss.

The last one aligns with the label rather than departing from it. Zepbound directs increases no sooner than every four weeks based on tolerability and response, and names 5, 10 and 15 mg as maintenance dosages — there is nothing requiring anyone to reach the top.

What this means for choosing a programme

A programme that escalates on a fixed calendar without assessment is not doing this work. Ask what is measured before starting, what is re-measured, and what would make the prescriber slow down.

It also has a pricing consequence. If the lowest effective dose is a legitimate destination, a flat-rate programme's advantage narrows — you may not reach the doses where dose-tiered pricing becomes punitive. That is an argument for comparing at the dose you expect to hold, not at the maximum.

What we will not tell you

Specific protein targets or training prescriptions. Those depend on your renal function, your existing conditions and your capacity, and a number published for a general audience is the wrong instrument. Ask a clinician or a dietitian who can see your bloods.

What the general weight-loss literature supports

Outside the GLP-1 context, the evidence that resistance training and adequate protein attenuate lean-mass loss during caloric restriction is reasonably strong and long-standing. It is why the recommendations appear so confidently in commentary: the principle is not novel and the physiology is understood.

The gap is specificity. GLP-1-driven loss can be faster and larger than dietary restriction typically produces, appetite suppression may reduce protein intake precisely when more is wanted, and neither variable has been isolated in a trial of this drug class.

Why appetite suppression complicates the protein advice

The mechanism that produces weight loss also reduces the volume of food a person wants. Advice to increase protein intake therefore competes with the drug's primary effect, which is a practical problem rather than a theoretical one.

This is one of the clearer arguments for dietetic input alongside prescribing, and one of the clearer gaps in telehealth models that supply medication without it. It is worth asking any provider whether dietetic support is included, billed separately, or absent.

What monitoring would look like if it were routine

Baseline and periodic body composition assessment. Grip strength or a functional measure, which is cheap and almost never done. Attention to intake adequacy rather than only to weight. And escalation decisions informed by those measures rather than by a calendar.

Very little of this happens in practice, in any care model. Naming it is useful because it lets you ask.

The honest summary

Muscle loss on these drugs is real and quantified. Whether the standard advice prevents functional decline is plausible and unproven. And the one intervention with trial evidence behind it — myostatin inhibition — is not available outside research.

That combination argues for monitoring rather than for either complacency or alarm.

Questions readers actually ask